Feature

Dan Kastner wins Crafoord Prize in Polyarthritis


 

The Royal Swedish Academy of Sciences and the Crafoord Foundation in Lund has awarded Daniel Kastner, MD, PhD, its 2021 Crafoord Prize in Polyarthritis, “for establishing the concept of autoinflammatory diseases.” The prize, named after the donor Holger Crafoord because of his bout with severe rheumatoid arthritis toward the end of his life, is for 6 million Swedish kronor (approximately USD $700,000).

Dr. Kastner, scientific director at the U.S. National Human Genome Research Institute’s division of intramural research, received the award for identifying the mechanisms responsible for familial Mediterranean fever, tumor necrosis factor receptor–associated periodic syndrome, and other diagnoses within the group of autoinflammatory diseases.

“Dan Kastner is often called the father of autoinflammatory diseases, a title that he thoroughly deserves. His discoveries have taught us a great deal about the immune system and its functions, contributing to effective treatments that reduce the symptoms of diseases from which patients previously suffered enormously, sometimes leading to premature death,” Olle Kämpe, chair of the prize committee, said in a press announcement.

While the Crafoord Prize normally is awarded on a 3-year rotating basis for achievements in mathematics and astronomy, geosciences, and biosciences, the prize in polyarthritis is “only awarded when there has been scientific progress that motivates a prize,” according to the press release.

Recommended Reading

JIA guideline calls for earlier use of targeted therapies
MDedge Rheumatology
Should our patients really go home for the holidays?
MDedge Rheumatology
COVID-19 cases in children continue to set records
MDedge Rheumatology
Expanded indications likely for apremilast
MDedge Rheumatology
Obesity, hypoxia predict severity in children with COVID-19
MDedge Rheumatology
Teenage bone density declines following sleeve gastrectomy
MDedge Rheumatology
EULAR recommendations define strategies to improve adherence in RMDs
MDedge Rheumatology
Data call for biologics trials in undertreated juvenile arthritis subtype
MDedge Rheumatology
Maternal autoimmune disease raises children’s risk of ADHD
MDedge Rheumatology
Tofacitinib for RA misses the mark in safety study
MDedge Rheumatology